ICU Medical Inc: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 10, 2019 and accepted by EDGAR at May 10, 2019, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $330.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $195.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-01-01 to 2019-03-31 | $135.3m | us-gaap:GrossProfit |
| Research and development | 3 months2019-01-01 to 2019-03-31 | $12.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-01-01 to 2019-03-31 | $72.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | $30.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-01-01 to 2019-03-31 | $133.0k | us-gaap:InterestExpense |
| Income tax | 3 months2019-01-01 to 2019-03-31 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | $31.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | $1.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-01-01 to 2019-03-31 | $1.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-01-01 to 2019-03-31 | 21,551,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$21.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $28.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-03-31 | $296.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $920.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $1.61bn | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $238.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2019-03-31 | $1.28bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000883984-19-000017. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.